High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: The lymphoma working party of the European group for blood and marrow transplantation

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2227-2232

  Kyriakou, Charalampia ^a   Canals, Carmen ^a   Sibon, David ^a   Cahn, Jean Yves ^a   Kazmi, Majid ^a   Arcese, William ^a   Kolbe, Karin ^a   Gorin, Norbert Claude ^a   Thomson, Kristy ^a   Milpied, Noel ^a   Niederwieser, Dietger ^a   Indrák, Karel ^a   Corradini, Paolo ^a   Sureda, Anna ^a   Schmitz, Norbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RELAPSE; SECOND CANCER; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EUROPE; FEASIBILITY STUDY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NOTE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EUROPE; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA; WHOLE-BODY IRRADIATION; YOUNG ADULT;

EID: 77952314975     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.4905     Document Type: Article

References (22)

1. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003 (Pubitemid 36506291)
2. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases. J Clin Oncol 11:1553-1558, 1993 (Pubitemid 23228262)
3. García-Sanz R, Montoto S, Torrequebrada A, et al: Waldenström macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 115:575-582, 2001 (Pubitemid 34019184)
4. Morel P, Monconduit M, Jacomy D, et al: Patients with the description of a new scoring system and its validation on 253 other patients. Blood 96:852-858, 2000
5. Dimopoulos MA, Alexanian R: Waldenstrom's macroglobulinemia. Blood 83:1452-1459, 1994 (Pubitemid 24081555)
6. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al: Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23:1564-1577, 2005
7. Kyle RA, Greipp PR, Gertz MA, et al: Waldenström's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000 (Pubitemid 30304504)
8. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004
9. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442-3446, 2006
10. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25:3344-3349, 2007 (Pubitemid 47325621)
11. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570-1575, 2007 (Pubitemid 46733084)
12. Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552, 2008
13. Anagnostopoulos A, Hari PN, Pérez WS, et al: Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 12:845-854, 2006 (Pubitemid 44096738)
14. Dreger P, Schmitz N: Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia. Biol Blood Marrow Transplant 13:623-624, 2007 (Pubitemid 46585936)
15. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
16. Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 113:4163-4170, 2009
17. Kimby E, Treon SP, Anagnostopoulos A, et al: Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 6:380-383, 2006
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Klein JP, Rizzo JD, Zhang MJ, et al: Statistical methods for the analysis and presentation of the results of bone marrow transplants: Part 2. Regression modeling. Bone Marrow Transplant 28:1001-1011, 2001 (Pubitemid 34030645)
20. Dhedin N, Tabrizi R, Bulabois PE, et al: Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (WM), update of the French experience in 54 cases. Haematologica 92, 2007 (suppl 2; abstr PO-1229)
21. Leleu X, Soumerai J, Roccaro A, et al: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 27:250-255, 2009
22. Dispenzieri A, Kyle R, Merlini G, et al: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:215-224, 2009